Hodder and Taylors

BioConsortia has secured $15 million in fresh equity funding to accelerate commercialization of Always N and Zaffre. Stronger reported adoption in New Zealand and promising corn yield trials support expansion, but manufacturing economics, regulatory approvals and consistent field performance remain central to its global ambitions.